Playback speed
10 seconds
Lecture Summary - ASCO 2022 Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Localized TNBC: Results From the NeoSTAR Trial
By
ASCO 2022 Conference Coverage
FEATURING
Laura Spring
By
ASCO 2022 Conference Coverage
FEATURING
Laura Spring
37 views
June 21, 2022
Comments 0
Login to view comments.
Click here to Login
Recommended
AUTOPLAY